Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Tognon, Raquel ^a   Gasparotto, Elainy P L ^a   Neves, Renata P ^a   Nunes, Natália S ^a   Ferreira, Aline F ^a   Palma, Patrícia V B ^a   Kashima, Simone ^a   Covas, Dimas T ^a   Santana, Mary ^b   Souto, Elizabeth X ^b   Zanichelli, Maria Aparecida ^c   Simões, Belinda P ^a   De Souza, Ana Maria ^a   Castro, Fabíola A ^a,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Brigadeiro Hospital of São Paulo   (Brazil)

^c Institute for Cancer Treatment in Children ITACI   (Brazil)

^d Institute for Cancer Treatment in Children ITACI ^*  (Brazil)

Author keywords

Apoptosis; BCL2 family members; Chronic Myeloproliferative Neoplasms; JAK2 V617F allele burden; PRV1

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; PROTEIN BCL 2; VALINE; ALLOANTIGEN; APOPTOSIS REGULATORY PROTEIN; BAD PROTEIN, HUMAN; BAX PROTEIN, HUMAN; BIK PROTEIN, HUMAN; CD177 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; JAK2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN BAD; PROTEIN BAX;

A 1 GENE; ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; BAD GENE; BAX GENE; BCL XL GENE; BCLW GENE; BID GENE; BIK GENE; CONTROLLED STUDY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MYELOFIBROSIS; PRV 1 GENE; SPLENOMEGALY; THROMBOCYTHEMIA; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; MYELOID METAPLASIA; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; CASE-CONTROL STUDIES; FEMALE; GPI-LINKED PROTEINS; HUMANS; ISOANTIGENS; JANUS KINASE 2; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; RNA, MESSENGER; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84856461503     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-2     Document Type: Article

References (42)

1. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Tefferi A, Vardiman JW, Leukemia 2008 22 14 22 10.1038/sj.leu.2404955 17882280
2. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis. Anastasi J, Hematol Oncol Clin North Am 2009 23 693 708 10.1016/j.hoc.2009.04.002 19577165
3. New mutations and pathogenesis of myeloproliferative neoplasms. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA, Blood 2011
4. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W, Nature 2005 434 1144 1148 10.1038/nature03546 15793561 (Pubitemid 40663494)
5. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. B Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Lancet 2005 365 1054 1061 15781101 (Pubitemid 40386783)
6. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG, Cancer Cell 2005 7 387 397 10.1016/j.ccr.2005.03.023 15837627 (Pubitemid 40544655)
7. A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC, N Engl J Med 2005 352 1779 1790 10.1056/NEJMoa051113 15858187 (Pubitemid 40570926)
8. Identification of an acquired JAK2 mutation in polycythemia vera. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ, J Biol Chem 2005 280 22788 22792 10.1074/jbc.C500138200 15863514 (Pubitemid 40853184)
9. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilland DG, Lodish HF, Green AR, N Engl J Med 2007 356 459 468 10.1056/NEJMoa065202 17267906 (Pubitemid 46193073)
10. Mutation in TET2 in myeloid cancers. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard AO, N Engl J Med 2009 360 2289 2301 10.1056/NEJMoa0810069 19474426
11. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, Kreil S, Jones A, Score J, Metzgeroth G, Oscier D, Hall A, Brandts C, Serve H, Reiter A, Chase AJ, Cross NC, Blood 2009 113 6182 6192 10.1182/blood-2008-12-194548 19387008
12. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL, PLoS Med 2006 3 270 10.1371/journal.pmed. 0030270 16834459 (Pubitemid 44125998)
13. Mutations of ASXL1 gene in myeloproliferative neoplasms. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adélade J, Rey J, Vainchenker W, Bernard OA, Chaffanet M, Vey N, Birnbaum D, Mozziconacci MJ, Leukemia 2009 23 2183 2186 10.1038/leu.2009.141 19609284
14. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC, Eur J Haematol 2007 79 508 515 10.1111/j.1600-0609.2007.00960.x 17961178 (Pubitemid 350126669)
15. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H, Pahl HL, Ann Hematol 2004 83 364 370 10.1007/s00277-004-0864-9 15034760 (Pubitemid 38684449)
16. Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines. Dillon M, Minear J, Johnson J, Lannutti BJ, Leuk Res 2008 32 811 819 10.1016/j.leukres.2007.09.018 17980909 (Pubitemid 351323938)
17. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Temerinac S, Klippel S, Strunck E, Röder S, Lübbert M, Lange W, Azemar M, Meinhardt G, Schaefer HE, Pahl HL, Blood 2000 95 2569 2576 10753836 (Pubitemid 30210535)
18. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, Leichtle R, Green AR, Griesshammer M, Heimpel H, Pahl HL, Blood 2003 102 3569 3574 10.1182/blood-2003-03-0919 12893745 (Pubitemid 37409372)
19. JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia. Melis S, Vellinga S, Zachée P, Sierens AC, De Schouwer PJ, Acta Clin Belg 2009 64 429 433 19999391
20. The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Zivny J, Klener P, Pytlik R, Andera L, Curr Pharm Des 2010 16 11 33 10.2174/138161210789941883 20214615
21. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Thomadaki H, Scorilas A, Crit Rev Clin Lab Sci 2006 43 1 67 10.1080/10408360500295626 16531274 (Pubitemid 43379211)
22. Analysis of apoptosis regulatory genes expression in the bone marrow (BM) of adult de novo myelodysplastic syndromes (MDS). Economopoulou C, Pappa V, Kontsioti F, Papageorgiou S, Kapsimali V, Papasteriadi C, Economopoulou P, Papageorgiou E, Dervenoulas J, Economopoulos T, Leuk Res 2008 32 61 69 10.1016/j.leukres.2007.04.012 17597205 (Pubitemid 350100841)
23. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Del Poeta G, Bruno A, Del Principe MI, Venditti A, Maurillo L, Buccisano F, Stasi R, Neri B, Luciano F, Siniscalchi A, de Fabritiis P, Amadori S, Curr Cancer Drug Targets 2008 8 207 222 10.2174/156800908784293640 18473734 (Pubitemid 351666857)
24. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. Tognon R, Gasparotto EP, Leroy JM, Oliveira GL, Neves RP, Carrara ReC, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Velano CE, Simões BP, Alberto FL, Miyashiro K, de Souza AM, Amarante-Mendes GP, de Castro FA, J Clin Pathol 2011 64 75 82 10.1136/jcp.2010.080895 21045235
25. The effect of the JAK2 V617F mutation on PRV-1 expression. Mnjoyan Z, Yoon D, Li J, Delhommeau F, Afshar-Kharghan V, Haematologica 2006 91 411 412 16503546
26. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, Passamonti F, Pietra D, Cazzola M, Skoda RC, Blood 2005 106 3374 3376 10.1182/blood-2005-05-1889 16081684 (Pubitemid 41609168)
27. Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. Olsson A, Norberg M, Okvist A, Derkow K, Choudhury A, Tobin G, Celsing F, Osterborg A, Rosenquist R, Jondal M, Osorio LM, Br J Cancer 2007 97 769 777 10.1038/sj.bjc.6603951 17726463 (Pubitemid 47396296)
28. Overexpression of the Anti-Apoptotic Genes mcl-1, bcl-w, bcl-xL and a1 Is Correlated with Chronic Myelogenous Leukemia Progression and Resistance to Gleevec [abstract]. Castro FA, Jacysyn JF, Ulbrich AG, Tobo PR, Lopes LR, Colassantti MD, Camanho D, Zanichelli MA, Hamerschlak N, Cavalheiro RC, Oliveira JSR, Amarante-Mendes GP, ASH Annual Meeting Abstracts 2005 106 2880
29. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Frenzel A, Grespi F, Chmelewskij W, Villunger A, Apoptosis 2009 14 584 596 10.1007/s10495-008-0300-z 19156528
30. Dysregulation of apoptosis in hepatocellular carcinoma cells. Fabregat I, World J Gastroenterol 2009 15 513 520 10.3748/wjg.15.513 19195051
31. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R, Leukemia 2005 19 1248 1252 10.1038/sj.leu.2403784 15902294 (Pubitemid 40946011)
32. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C, Blood 2005 105 3303 3311 10.1182/blood-2004-02-0749 15626746
33. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL, Mol Cell Biol 2001 21 7653 7662 10.1128/MCB.21.22. 7653-7662.2001 11604501 (Pubitemid 32988776)
34. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia. Zhang L, Zhao H, Sun A, Lu S, Liu B, Tang F, Feng Y, Zhao L, Yang R, Han ZC, Haematologica 2004 89 1199 1206 15477204 (Pubitemid 39390444)
35. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH, Leukemia 2006 20 1800 1808 10.1038/sj.leu.2404338 16871275 (Pubitemid 44574991)
36. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival. Rubert J, Qian Z, Andraos R, Guthy DA, Radimerski T, BMC Cancer 2011 11 24 10.1186/1471-2407-11-24 21247487
37. The BCL-2 family reunion. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR, Mol Cell 2010 37 299 310 10.1016/j.molcel.2010.01.025 20159550
38. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Chipuk JE, Green DR, Trends Cell Biol 2008 18 157 164 10.1016/j.tcb.2008.01.007 18314333
39. The role of STATs in apoptosis. Battle TE, Frank DA, Curr Mol Med 2002 2 381 392 10.2174/1566524023362456 12108949 (Pubitemid 35452886)
40. STAT proteins as novel targets for cancer drug discovery. Turkson J, Expert Opin Ther Targets 2004 8 409 422 10.1517/14728222.8.5.409 15469392 (Pubitemid 39359648)
41. Detection of abnormalities of PRV-1, TPO, and c-MPL genes detected by fluorescence in situ hybridization in essential thrombocythemia. Puigdecanet E, Espinet B, Villa O, Florensa L, Besses C, Serrano S, Solé F, Cancer Genet Cytogenet 2006 167 39 42 10.1016/j.cancergencyto.2005.08.016 16682284
42. The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia. Johansson P, Andréasson B, Safai-Kutti S, Wennström L, Palmqvist L, Ricksten A, Lindstedt G, Kutti J, Eur J Haematol 2003 70 358 362 10.1034/j.1600-0609.2003.00079.x 12756017 (Pubitemid 36713930)